<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Neuropsychopharmacol</journal-id><journal-id journal-id-type="publisher-id">ijnp</journal-id><journal-title-group><journal-title>International Journal of Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1461-1457</issn><issn pub-type="epub">1469-5111</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5616686</article-id><article-id pub-id-type="doi">10.1093/ijnp/pyw043.089</article-id><article-id pub-id-type="publisher-id">pyw043.089</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Sunday Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>PS89. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Kiwon</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>Ikki</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Woo</surname><given-names>Jong-Min</given-names></name><xref ref-type="aff" rid="aff4">d</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Seung-Hwan</given-names></name><xref ref-type="aff" rid="aff5">e</xref></contrib><contrib contrib-type="author"><name><surname>Fava</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="aff3">c</xref></contrib><contrib contrib-type="author"><name><surname>Mischoulon</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff3">c</xref></contrib><contrib contrib-type="author"><name><surname>Papakostas</surname><given-names>George I.</given-names></name><xref ref-type="aff" rid="aff3">c</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Eui-Joong</given-names></name><xref ref-type="aff" rid="aff6">f</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Seock hoon</given-names></name><xref ref-type="aff" rid="aff7">g</xref></contrib><contrib contrib-type="author"><name><surname>Ha</surname><given-names>Jee Hyun</given-names></name><xref ref-type="aff" rid="aff8">h</xref></contrib><contrib contrib-type="author"><name><surname>Jeon</surname><given-names>Hong Jin</given-names></name><xref ref-type="aff" rid="aff1">a</xref><xref ref-type="aff" rid="aff2">b</xref><xref ref-type="aff" rid="aff3">c</xref></contrib></contrib-group><aff id="aff1">
<label>a</label>Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</aff><aff id="aff2">
<label>b</label>Department of Clinical Research Design and Evaluation, and Department of Medical Device Management and Research, Samsung Advanced Institute for Health Sciences &#x00026; Technology (SAIHST), Seoul, Korea</aff><aff id="aff3">
<label>c</label>Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, USA</aff><aff id="aff4">
<label>d</label>Department of Psychiatry, Seoul Paik Hospital, Inje University School of Medicine, Seoul, Korea</aff><aff id="aff5">
<label>e</label>Department of Psychiatry, Ilsan Paik Hospital, Inje University School of Medicine, Ilsan, Korea</aff><aff id="aff6">
<label>f</label>Department of Psychiatry, Eulji University School of Medicine, Eulji General Hospital, Seoul, Korea</aff><aff id="aff7">
<label>g</label>Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea</aff><aff id="aff8">
<label>h</label>Department of Psychiatry, Konkuk University School of Medicine, Seoul, Korea</aff><pub-date pub-type="collection"><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub" iso-8601-date="2016-05-27"><day>27</day><month>5</month><year>2016</year></pub-date><volume>19</volume><issue>Suppl 1</issue><fpage seq="i">30</fpage><lpage>31</lpage><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</copyright-statement><copyright-year>2016</copyright-year></permissions><self-uri xlink:href="pyw043.089.pdf"/><counts><page-count count="2"/></counts></article-meta></front><body><p>
<bold>Abstract</bold>
</p><p>
<bold>Background:</bold> Previous research has reported evidence that patients with major depressive disorder (MDD) show anxiety symptoms and neurocognitive impairments. However, the influence of anxiety on neurocognitive function in MDD patients during antidepressant treatment is unclear.</p><p>
<bold>Method:</bold> MDD patients (n=164) completed a 12-week, multicenter, randomized trial assigned in a 1:1 ratio to either tianeptine or escitalopram. Changes of anxiety symptoms were assessed by the Hamilton Anxiety Rating Scale (HAM-A), and the Hamilton Depression Rating Scale (HAM-D), self-rated subjective cognitive impairment on memory and concentration, the Mini-Mental Status Examination (MMSE), Continuous Performance Test (CPT), Verbal Learning Test (VLT), and Raven's Progressive Matrices (RPM) were assessed every 4 weeks.</p><p>
<bold>Results:</bold> During 12 weeks of treatment, decrease in the HAM-A score was significantly associated with improvement of subjective cognitive impairments on memory (p&#x0003c;0.001) and concentration (p&#x0003c;0.001), and objective measures on delayed memory (p=0.006) and reasoning ability (p=0.002), after adjusting for covariates such as baseline HAM-A scores, time, sex, age, education years and assigned medication using the Mixed effects and Generalized Estimated Equation model analysis. However, the other cognitive outcome variables, immediate memory, commission error, and MMSE, which showed significant improvement through 12-week study period, showed no significant association with improvement of anxiety.</p><p>
<bold>Conclusion:</bold> Improvement of anxiety symptoms was significantly associated with improvement in subjective and objective neurocognitive functions such as delayed memory and reasoning ability in elderly MDD patients during antidepressant treatment, but not significantly associated with improvement of immediate memory and commission error.</p></body></article>